MY-943

• CAT Number: I041228
• Molecular Formula: C30H36N4O6S2
• Molecular Weight: 612.76
• Purity: ≥95%
• Synonyms: [2-[N-[(3-hydroxy-4-methoxyphenyl)methyl]-3,4,5-trimethoxyanilino]-2-oxoethyl] 4-(4-aminophenyl)piperazine-1-carbodithioate
• InChI: InChI=1S/C30H36N4O6S2/c1-37-25-10-5-20(15-24(25)35)18-34(23-16-26(38-2)29(40-4)27(17-23)39-3)28(36)19-42-30(41)33-13-11-32(12-14-33)22-8-6-21(31)7-9-22/h5-10,15-17,35H,11-14,18-19,31H2,1-4H3
• InChIKey: IQDDCWYNBRRRQG-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)CN(C2=CC(=C(C(=C2)OC)OC)OC)C(=O)CSC(=S)N3CCN(CC3)C4=CC=C(C=C4)N)O

MY-943 is a potent tubulin polymerization and LSD1 inhibitor with anticancer activity. MY-943 induces G2/M phase arrest and apoptosis, and inhibits cell migration. MY-943 can be used for gastric cancer research[1].
MY-943 exhibits the anti-proliferative activities against three kinds of cancer cells with IC50 values of 0.019 μM for MGC-803, 0.044 μM for HCT-116 and 0.030 μM for KYSE450[1].
MY-943 (10, 20, 30 nM; 20, 40, 48, 60 h) dose-dependently and time-dependently inhibits the cell viability of MGC-803 and SGC-7901 cells[1].
MY-943 (1, 5, 10 μm; 48 h) dose-dependently weakens the alkylation of β-tubulin in the presence of EBI, and prevents the formation of β-tubulin:EBI adduct band in MGC-803 and SGC-7901 cells[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) concentration-dependently inhibits tubulin polymerization in MGC-803 and SGC-7901 cells[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) dose-dependently induces cell apoptosis[1].
MY-943 dose-dependently down-regulates the expression levels of Bcl-2 and Mcl-1 (anti-apoptotic proteins), and dose-dependently increases the expression levels of cleaved Caspase-3 and Caspase-7[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) dose-dependently down-regulates the expression levels of Weel, CyclinB1 and CDC2, and dose-dependently increases the expression levels of p-Histone H3, H3K4me1 and H3K4me2[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) effectively and dose-dependently induces G2/M phase arrest[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) significantly inhibits the migration ability of gastric cancer cells MGC-803 and SGC-7901[1].
MY-943 (25 mg/kg/day; i.p.; 21 days) significantly inhibits the growth of gastric cancer and greatly reduces the weight and volume of the tumor tissues in mice[1].

Reference

[1]. Yuan XY, et al. Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers. Eur J Med Chem. 2023 Apr 5;252:115281.
 [Content Brief]